Watchlist

Watchlist
Achaogen, Inc. (AKAO)
Nasdaq Biotech Index: 54 to be added, 15 removed
Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more …
Biotech drug pricing should not get substantially worse next year - Mizuho
In an interview with Bloomberg News, Mizuho Securities' Salim Syed says pricing in the biotech sector is "not getting any better" but "will not get substantially worse" in 2018. He says pricing and M&A activity will be key areas next year and beyond after a slowdown in deals this year. …
Introducing Second-Level Investing: The Reference For Discerning Life Sciences Investors
(Editors' Note: This article is meant as an introduction for Second-Level Investing , a new Marketplace service by Jrme Verony). Fig. 1 : The unfathomable significance of the unseen. Illustration of dark matter distribution as measured from earth (left to right). Note t…
Achaogen 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Achaogen in conjunction with their 2017 Q3 earnings Read more …
Achaogen's (AKAO) CEO Kenneth Hillan on Q3 2017 Results - Earnings Call Transcript
Achaogen, Inc. (AKAO) Q3 2017 Results Earnings Conference Call November 8, 2017 04:30 PM ET Executives David Arrington - VP, IR and Corporate Communications Kenneth Hillan - CEO Blake Wise - President and COO Janet Dorling - Chief Commercial Officer Toby Schilke - CFO Anal…
Achaogen misses by $0.13, misses on revenue
Achaogen (NASDAQ: AKAO ): Q3 EPS of -$0.85 misses by $0.13 . Revenue of $0.6M (-96.3% Y/Y) misses by $1.34M . Press Release More news on: Achaogen, Earnings news and commentary, Healthcare stocks news,
Notable earnings after Wednesday's close
AEZS , AFSI , AKAO , ALB , ALDW , ALRM , AMBC , AMPH , AMRS , ANDV , ANDX , ANGI , APU , ATHX , ATO , BKCC , BLDR , BREW , BRS , BW , CAPR , CASC , CBAY , CDTX , CHEF , CLNS , CODI , COGT , COLL , CPA , CSOD , CTL , CTRE , CXW , DK , DKL , DOX , ECR , …
Can Achaogen Turn It Around After A Long Slide?
Bursting onto the biotech scene in December 2016 after positive clinical trials for its antibiotic candidate plazomicin, Achaogen, Inc. (NASDAQ: AKAO ) soared several hundred percent in just a few months to trade in the high $20 range in the first half of 2017. Beginning in May, however, AKAO…
4 Biotech Stocks Worth Buying A Pullback In
The biotech sector has done quite well year to date, both in comparison to other key indices as well as on an absolute basis. IBB data by YCharts The past few days have brought a bit of weakness, which one could say is expected and healthy as recent gains are digested. In actuali…
Biotech Forum Daily Digest: Revisiting Achaogen After A Recent Decline
"Conscience is the inner voice that warns us somebody may be looking."- H.L. Mencken The main biotech indices continue to see not much in the way of trading action here so far in the fourth quarter. There is little current movement in the large caps of the sector and probably will not be u…
Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of Top Seeking Alpha Coverage: MannKind Today we will discuss a MannKind ( MNKD ) a…
Achaogen, Inc. (AKAO)